National Academies Press: OpenBook

The Anthrax Vaccine: Is It Safe? Does It Work? (2002)

Chapter: Appendix G DMSS Analyses Requested by the IOM Committee to Assess the Safety and Efficacy of the Anthrax Vaccine

« Previous: Appendix F Anthrax Vaccine Expert Committee (AVEC) Case Assessment Form
Suggested Citation:"Appendix G DMSS Analyses Requested by the IOM Committee to Assess the Safety and Efficacy of the Anthrax Vaccine." Institute of Medicine. 2002. The Anthrax Vaccine: Is It Safe? Does It Work?. Washington, DC: The National Academies Press. doi: 10.17226/10310.
×

Appendix G
DMSS Analyses Requested by the IOM Committee to Assess the Safety and Efficacy of the Anthrax Vaccine

Suggested Citation:"Appendix G DMSS Analyses Requested by the IOM Committee to Assess the Safety and Efficacy of the Anthrax Vaccine." Institute of Medicine. 2002. The Anthrax Vaccine: Is It Safe? Does It Work?. Washington, DC: The National Academies Press. doi: 10.17226/10310.
×

TABLE G-1 Among Service Members Receiving at Least One Dose of AVA Hospitalization Diagnoses with Rate Ratios Above 1.0, U.S. Armed Forces, Active Duty, 1998 to 2000

ICD-9-CM Code(s)

Description

Anthrax Immunization Status

Adjusted Rate Ratio

95% Confidence Intervals

Post

Pre

Number

Rate per 100,000

Number

Rate per 100,000

193

Malignant neoplasm of thyroid gland

41

5.6

9

1.9

2.40

1.05

5.49

233

Carcinoma in situ of breast and genitourinary system

19

2.6

5

1.0

5.14

1.81

14.57

250

Diabetes mellitus

67

9.1

8

1.7

3.46

1.51

7.90

296

Affective psychoses

600

81.3

120

25.1

2.15

1.71

2.71

298

Other nonorganic psychoses

69

9.3

14

2.9

2.50

1.29

4.83

309

Adjustment reaction

1,219

165.1

403

84.3

1.38

1.20

1.59

311

Depressive disorder, not elsewhere classified

187

22.6

46

9.6

1.79

1.21

2.66

374

Other disorders of eyelids

16

2.2

7

1.5

2.71

1.05

7.00

550

Inguinal hemia

293

39.7

172

35.0

1.31

1.04

1.65

569

Other disorders of intestine

34

4.6

6

1.3

2.94

1.23

7.07

724

Other and unspecified disorders of back

108

14.6

38

7.9

1.51

1.04

2.20

726

Peripheral enthesopathies and allied syndromes

213

28.8

97

20.3

1.29

1.01

1.64

732

Osteochondropathies

38

5.1

11

2.3

2.03

1.03

3.98

808

Fracture of pelvis

53

7.2

16

3.3

1.81

1.03

3.20

823

Fracture of tibia and fibula

169

22.9

60

12.5

1.63

1.14

2.32

Suggested Citation:"Appendix G DMSS Analyses Requested by the IOM Committee to Assess the Safety and Efficacy of the Anthrax Vaccine." Institute of Medicine. 2002. The Anthrax Vaccine: Is It Safe? Does It Work?. Washington, DC: The National Academies Press. doi: 10.17226/10310.
×

TABLE G-2 Among Service Members Receiving at Least One Dose of AVA, Hospitalization Diagnoses with Rate Ratios Above 1.0, by Number of Days after Immunization, U.S. Armed Forces, Active Duty, 1998 to 2000

ICD-9-CM Code(s)

Description

Anthrax immunization Status

Comparison*

Pre

0-45 days

>45days

0-45/Pre

>45/Pre

Number

Rate per 100,000

Number

Rate per 100,000

Number

Rate per 100,000

Adjusted Rate Ratio

98% CI

Adjusted Rate Ratio

95% CI

193

Malignant neoplasm of thyroid gland

9

1.88

10

6.04

31

5.41

2.88

1.12

7.37

2.16

0.90

5.17

220

Benign neoplasm of ovary

9

1.88

8

4.83

12

2.10

2.61

1.01

6.77

1.13

0.48

2.68

233

Carcinoma in situ of breast and genitourinary system

5

1.05

5

3.02

14

2.44

4.12

1.17

14.49

5.85

1.95

17.58

250

Diabetes mellitus

8

1.67

13

7.85

54

9.43

3.49

1.39

8.79

3.44

1.47

8.06

296

Affective psychoses

120

25.10

102

61.56

498

86.96

1.84

1.39

2.43

2.31

1.82

2.94

298

Other nonorganic psychoses

14

2.93

9

5.43

60

10.48

1.52

0.64

3.62

3.08

1.55

6.13

304

Drug dependence

6

1.25

2

1.21

33

5.76

.

.

.

3.06

1.08

8.66

309

Adjustment reaction

403

84.29

258

155.72

961

167.80

1.37

1.16

1.62

1.38

1.19

1.61

311

Depressive disorder, not elsewhere classified

46

9.62

35

21.12

132

23.05

1.78

1.11

2.84

1.80

1.19

2.72

312

Disturbance of conduct, not elsewhere classified

6

1.25

0

0.00

12

2.10

.

.

.

1.41

1.41

1.41

414

Other forms of chronic ischemic heart disease

18

3.76

20

12.07

81

14.14

2.15

1.09

4.23

1.65

0.89

3.07

429

III-defined desoriptions and complications of heart disease

6

1.25

0

0.00

12

2.10

.

.

.

1.32

1.32

1.32

451

Phlebitis and thrombophlebitis

5

1.05

0

0.00

12

2.10

.

.

.

1.58

1.58

1.58

470

Deviated nasal septum

45

9.41

23

13.88

90

15.72

1.19

0.72

1.97

1.47

1.02

2.11

493

Asthma

41

8.58

30

18.11

64

11.18

1.83

1.14

2.93

1.10

0.74

1.64

541

Appendicitis, unqualified

47

9.83

19

11.47

77

13.45

1.15

0.68

1.97

1.46

1.01

2.11

550

Inguinal hernia

172

35.98

76

45.87

217

37.89

1.24

0.93

1.65

1.36

1.05

1.76

569

Other disorders of intestine

6

1.25

10

6.04

24

4.19

4.16

1.51

11.49

2.61

1.06

6.44

598

Urethral stricture

22

5.18

8

5.38

51

9.89

0.96

0.43

2.16

1.66

1.00

2.75

622

Noninflammatory disorders of cervix

15

28.20

22

129.54

48

84.26

2.64

1.30

5.35

1.55

0.78

3.09

724

Other and unspecified disorders of back

38

7.95

19

11.47

89

15.54

1.25

0.72

2.18

1.59

1.08

2.33

733

Other disorders of bone and cartilage

95

19.87

45

27.16

194

33.87

1.12

0.77

1.62

1.45

1.06

1.98

735

Acquired deformities of toe

34

7.11

20

12.07

83

14.49

1.15

0.66

2.01

1.58

1.06

2.37

808

Fracture of pelvis

16

3.35

11

6.64

42

7.33

1.66

0.77

3.60

1.86

1.04

3.34

823

Fracture of tibia and fibula

60

12.55

36

21.73

133

23.22

1.53

0.99

2.37

1.68

1.15

2.46

865

Injury to spleen

9

1.88

10

6.04

19

3.32

2.83

1.15

6.99

1.61

0.72

3.58

999

Complications of medical care, not elsewhere classified

7

1.46

5

3.02

5

0.87

3.70

1.05

13.04

1.25

0.30

5.11

Suggested Citation:"Appendix G DMSS Analyses Requested by the IOM Committee to Assess the Safety and Efficacy of the Anthrax Vaccine." Institute of Medicine. 2002. The Anthrax Vaccine: Is It Safe? Does It Work?. Washington, DC: The National Academies Press. doi: 10.17226/10310.
×

TABLE G-3 Among Service Members Receiving at Least One Dose of AVA, Hospitalization Diagnoses with Rate Ratios Above 1.0, by Number of Doses After Immunization, U.S. Armed Forces, Active Duty, 1998 to 2000

 

Anthrax Immunization Status

Comparison

Pre

1 to 3 doses

4 or more doses

1 to 3 doses/Pre

4 or more/Pre

ICD-9-CM

Description

Number

Rate/100,000

Number

Rate/100,000

Number

Rate/100,000

Adjusted Rate ratio

95% CI

Adjusted Rate ratio

95% CI

193

Malignant neoplasm of thyroid gland

9

1.88

12

6.51

29

5.23

2.55

0.94-6.94

2.35

1.01-5.48

225

Benign neoplasm of brain and other parts of nervous system

6

1.25

8

4.34

6

1.08

2.99

1.02-8.77

0.70

0.22-2.19

250

Diabetes mellitus

8

1.67

24

13.02

43

7.76

4.98

2.02-12.25

3.05

1.31-7.09

296

Affective psychoses

120

25.10

229

124.27

371

66.95

3.65

2.81-4.74

1.79

1.42-2.27

298

Other nonorganic psychoses

14

2.93

26

14.11

43

7.76

4.08

1.92-8.68

2.11

1.07-4.18

300

Neurotic disorders

69

14.43

70

37.99

101

18.23

2.20

1.46-3.30

0.92

0.64-1.32

301

Personality disorders

64

13.39

115

62.41

81

14.62

1.95

1.32-2.87

0.69

0.46-1.02

304

Drug dependence

6

1.25

13

7.05

22

3.97

4.20

1.37-12.91

1.81

0.64-5.07

309

Adjustment reaction

403

84.29

460

249.63

759

136.98

2.28

1.94-2.69

1.16

1.00-1.34

311

Depressive disorder, not elsewhere classified

46

9.62

49

26.59

118

21.30

2.60

1.62-4.20

1.63

1.09-2.44

346

Migraine

36

7.53

30

16.28

46

8.30

1.82

1.12-2.98

0.90

0.58-1.40

Suggested Citation:"Appendix G DMSS Analyses Requested by the IOM Committee to Assess the Safety and Efficacy of the Anthrax Vaccine." Institute of Medicine. 2002. The Anthrax Vaccine: Is It Safe? Does It Work?. Washington, DC: The National Academies Press. doi: 10.17226/10310.
×

348

Other conditions of brain

7

1.46

9

4.88

8

1.44

2.80

1.03-7.63

0.78

0.28-2.19

410

Acute myocardial infarction

22

4.60

24

13.02

44

7.94

2.60

1.42-4.75

1.15

0.69-1.94

470

Deviated nasal septum

45

9.41

18

9.77

95

17.14

1.15

0.65-2.00

1.47

1.02-2.10

493

Asthma

41

8.58

36

19.54

58

10.47

2.18

1.37-3.47

1.00

0.67-1.51

550

Inguinal hernia

172

35.98

55

29.85

238

42.95

1.24

0.88-1.75

1.32

1.04-1.68

555

Regional enteritis

5

1.05

19

10.31

20

3.61

4.90

1.55-15.44

1.96

0.65-5.95

569

Other disorders of intestine

6

1.25

6

3.26

28

5.05

2.05

0.66-6.41

3.24

1.33-7.89

724

Other and unspecified disorders of back

38

7.95

26

14.11

82

14.80

1.78

1.06-2.98

1.45

0.98-2.13

726

Peripheral enthesopathies and allied syndromes

97

20.29

57

30.93

156

28.15

1.49

1.07-2.09

1.04

0.80-1.34

732

Osteochondropathies

11

2.30

6

3.26

32

5.78

1.50

0.55-4.12

2.17

1.09-4.32

733

Other disorders of bone and cartilage

95

19.87

68

36.90

171

30.86

1.77

1.22-2.56

1.23

0.91-1.66

735

Acquired deformities of toe

34

7.11

12

6.51

91

16.42

0.93

0.48-1.82

1.60

1.07-2.39

808

Fracture of pelvis

16

3.35

15

8.14

38

6.86

2.47

1.20-5.09

1.64

0.91-2.98

813

Fracture of radius and ulna

102

21.33

54

29.30

114

20.57

1.62

1.10-2.37

1.13

0.83-1.54

823

Fracture of tibia and fibula

60

12.55

50

27.13

119

21.48

1.93

1.24-3.01

1.55

1.07-2.23

844

Sprains and strains of knee and leg

113

23.64

64

34.73

167

30.14

1.67

1.22-2.29

1.10

0.86-1.39

851

Cerebral laceration and contusion

8

1.67

2

1.09

22

3.97

-

-

2.43

1.08-5.47

891

Open wound of knee, leg [ except thigh ], and ankle

18

3.76

18

9.77

28

5.05

2.10

1.08-4.11

1.26

0.70-2.29

998

Other complications of procedures, not elsewhere classified

157

32.84

112

60.78

250

45.12

1.51

1.13-2.02

1.11

0.87-1.41

Suggested Citation:"Appendix G DMSS Analyses Requested by the IOM Committee to Assess the Safety and Efficacy of the Anthrax Vaccine." Institute of Medicine. 2002. The Anthrax Vaccine: Is It Safe? Does It Work?. Washington, DC: The National Academies Press. doi: 10.17226/10310.
×

TABLE G-4 Among all Service Members, Hospitalization Diagnoses with Rate Ratios Above 1.0, U.S. Armed Forces, Active Duty, 1998 to 2000

ICD-9-CM Code(s)

Description

Anthrax Immunization Status

Adjusted Rate Ratio

95% Confidence Intervals

Pre

Never

Number

Rate per 100,000

Number

Rate per 100,000

084

Malaria

18

3.8

62

2.1

1.76

1.04

2.99

695

Erythematous conditions

9

1.9

22

0.8

2.74

1.25

6.00

913

Superficial injury of elbow, forearm, and wrist

10

2.1

17

0.6

3.37

1.53

7.45

986

Toxic effect of carbon monoxide

8

1.7

8

0.3

7.49

2.74

20.46

993

Effects of air pressure

11

2.3

46

1.6

2.05

1.01

4.17

Suggested Citation:"Appendix G DMSS Analyses Requested by the IOM Committee to Assess the Safety and Efficacy of the Anthrax Vaccine." Institute of Medicine. 2002. The Anthrax Vaccine: Is It Safe? Does It Work?. Washington, DC: The National Academies Press. doi: 10.17226/10310.
×

TABLE G-5 Among All Service Members, Rates of Hospitalization for Specific Diagnoses and Adjusted Rate Ratios Comparing Hospitalization Rates Following at Least One Dose of AVA (“Post”) with Hospitalization Rates Before First AVA Dose (“Pre”), by Sex, U.S. Armed Forces, Active Duty, 1998 to 2000

 

ICD-9-CM Code(s)

Description

Anthrax Immunization Status

Adjusted Rate Ratio

95% Confidence Intervals

Post

Pre

Number

Rate per 100,000

Number

Rate per 100,000

Both Sexes

710-719

Arthropathies and related disorders

1,543

209.0

7,674

227.8

0.88

0.83

0.93

493

Asthma

94

12.7

629

18.7

0.63

0.51

0.79

710

Diffuse diseases of connective tissue

9

1.2

61

1.8

0.86

0.42

1.78

250

Diabetes mellitus

67

9.1

445

13.2

0.65

0.50

0.84

380-389

Diseases of the ear and mastoid process

67

9.1

368

10.9

0.87

0.67

1.14

357

Inflammatory and toxic neuropathy

13

1.8

89

2.6

0.75

0.41

1.35

427

Cardiac dysrhythmias

170

23.0

998

29.6

0.77

0.65

0.91

200-208

Lymphosarcoma and reticulosarcoma

43

5.8

311

9.2

0.70

0.51

0.97

340

Multiple sclerosis

32

4.3

103

3.1

1.31

0.87

1.98

410

Acute myocardial infarction

68

9.2

384

11.4

0.97

0.74

1.27

240-246

Disorders of thyroid gland

48

6.5

334

9.9

0.76

0.56

1.04

530-537

Diseases of esophagus, stomach, and duodenum

475

64.3

2,135

63.4

1.02

0.92

1.13

Suggested Citation:"Appendix G DMSS Analyses Requested by the IOM Committee to Assess the Safety and Efficacy of the Anthrax Vaccine." Institute of Medicine. 2002. The Anthrax Vaccine: Is It Safe? Does It Work?. Washington, DC: The National Academies Press. doi: 10.17226/10310.
×

 

ICD-9-CM Code(s)

Description

Anthrax Immunization Status

Adjusted Rate Ratio

95% Confidence Intervals

Post

Pre

Number

Rate per 100,000

Number

Rate per 100,000

Women

710-719

Arthropathies and related disorders

133

179.9

849

166.7

1.02

0.84

1.23

493

Asthma

21

28.4

197

38.7

0.67

0.42

1.06

710

Diffuse diseases of connective tissue

4

5.4

39

7.7

.

.

.

250

Diabetes mellitus

4

5.4

40

7.9

.

.

.

380-389

Diseases of the ear and mastoid process

10

13.5

73

14.3

1.11

0.56

2.18

357

Inflammatory and toxic neuropathy

3

4.1

16

3.1

.

.

.

427

Cardiac dysrhythmias

11

14.9

87

17.1

0.98

0.52

1.84

200-208

Lymphosarcoma and reticulosarcoma

3

4.1

45

8.8

.

.

.

340

Multiple sclerosis

15

20.3

34

6.7

2.14

1.14

4.01

410

Acute myocardial infarction

1

1.4

14

2.7

.

.

.

240-246

Disorders of thyroid gland

23

31.1

175

34.4

0.90

0.58

1.40

530-537

Diseases of esophagus, stomach, and duodenum

40

54.1

278

54.6

1.04

0.74

1.45

Men

710-719

Arthropathies and related disorders

1,410

212.2

6,825

238.7

0.86

0.81

0.91

493

Asthma

73

11.0

432

15.1

0.65

0.50

0.83

710

Diffuse diseases of connective tissue

5

0.8

22

0.8

0.85

0.32

2.25

250

Diabetes mellitus

63

9.5

405

14.2

0.65

0.50

0.85

380-389

Diseases of the ear and mastoid process

57

8.6

295

10.3

0.87

0.65

1.16

357

Inflammatory and toxic neuropathy

10

1.5

73

2.6

0.71

0.36

1.40

427

Cardiac dysrhythmias

159

23.9

911

31.9

0.76

0.64

0.90

200-208

Lymphosarcoma and reticulosamoma

40

6.0

266

9.3

0.76

0.54

1.08

340

Multiple sclerosis

17

2.6

69

2.4

1.00

0.58

1.73

410

Acute myocardial infarction

67

10.1

370

12.9

0.97

0.74

1.27

240-246

Disorders of thyroid gland

25

3.8

159

5.6

0.68

0.44

1.04

530-537

Diseases of esophagus, stomach, and duodenum

435

65.5

1,857

65.0

1.02

0.91

1.13

NOTE: Prevaccination population includes personnel who never received AVA.

Suggested Citation:"Appendix G DMSS Analyses Requested by the IOM Committee to Assess the Safety and Efficacy of the Anthrax Vaccine." Institute of Medicine. 2002. The Anthrax Vaccine: Is It Safe? Does It Work?. Washington, DC: The National Academies Press. doi: 10.17226/10310.
×
Page 245
Suggested Citation:"Appendix G DMSS Analyses Requested by the IOM Committee to Assess the Safety and Efficacy of the Anthrax Vaccine." Institute of Medicine. 2002. The Anthrax Vaccine: Is It Safe? Does It Work?. Washington, DC: The National Academies Press. doi: 10.17226/10310.
×
Page 246
Suggested Citation:"Appendix G DMSS Analyses Requested by the IOM Committee to Assess the Safety and Efficacy of the Anthrax Vaccine." Institute of Medicine. 2002. The Anthrax Vaccine: Is It Safe? Does It Work?. Washington, DC: The National Academies Press. doi: 10.17226/10310.
×
Page 247
Suggested Citation:"Appendix G DMSS Analyses Requested by the IOM Committee to Assess the Safety and Efficacy of the Anthrax Vaccine." Institute of Medicine. 2002. The Anthrax Vaccine: Is It Safe? Does It Work?. Washington, DC: The National Academies Press. doi: 10.17226/10310.
×
Page 248
Suggested Citation:"Appendix G DMSS Analyses Requested by the IOM Committee to Assess the Safety and Efficacy of the Anthrax Vaccine." Institute of Medicine. 2002. The Anthrax Vaccine: Is It Safe? Does It Work?. Washington, DC: The National Academies Press. doi: 10.17226/10310.
×
Page 249
Suggested Citation:"Appendix G DMSS Analyses Requested by the IOM Committee to Assess the Safety and Efficacy of the Anthrax Vaccine." Institute of Medicine. 2002. The Anthrax Vaccine: Is It Safe? Does It Work?. Washington, DC: The National Academies Press. doi: 10.17226/10310.
×
Page 250
Suggested Citation:"Appendix G DMSS Analyses Requested by the IOM Committee to Assess the Safety and Efficacy of the Anthrax Vaccine." Institute of Medicine. 2002. The Anthrax Vaccine: Is It Safe? Does It Work?. Washington, DC: The National Academies Press. doi: 10.17226/10310.
×
Page 251
Suggested Citation:"Appendix G DMSS Analyses Requested by the IOM Committee to Assess the Safety and Efficacy of the Anthrax Vaccine." Institute of Medicine. 2002. The Anthrax Vaccine: Is It Safe? Does It Work?. Washington, DC: The National Academies Press. doi: 10.17226/10310.
×
Page 252
Next: Appendix H An Assessment of the Safety of the Anthrax Vaccine: A Letter Report »
The Anthrax Vaccine: Is It Safe? Does It Work? Get This Book
×
Buy Paperback | $50.00 Buy Ebook | $39.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

The vaccine used to protect humans against the anthrax disease, called Anthrax Vaccine Adsorbed (AVA), was licensed in 1970. It was initially used to protect people who might be exposed to anthrax where they worked, such as veterinarians and textile plant workers who process animal hair. When the U. S. military began to administer the vaccine, then extended a plan for the mandatory vaccination of all U. S. service members, some raised concerns about the safety and efficacy of AVA and the manufacture of the vaccine. In response to these and other concerns, Congress directed the Department of Defense to support an independent examination of AVA.

The Anthrax Vaccine: Is It Safe? Does It Work? reports the study’s conclusion that the vaccine is acceptably safe and effective in protecting humans against anthrax. The book also includes a description of advances needed in main areas: improving the way the vaccine is now used, expanding surveillance efforts to detect side effects from its use, and developing a better vaccine.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!